Pleconaril

Pleconaril
Clinical data
Routes of
administration
Oral, intranasal
ATC code
Legal status
Legal status
  •  ?
Pharmacokinetic data
Bioavailability70% (oral)
Protein binding>99%
MetabolismHepatic
Excretion<1% excreted unchanged in urine
Identifiers
  • 3-{3,5-dimethyl-4-[3-(3-methylisoxazol-5-yl)propoxy]
    phenyl}-5-(trifluoromethyl)-1,2,4-oxadiazole
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
ChEMBL
PDB ligand
CompTox Dashboard (EPA)
ECHA InfoCard100.208.947
Chemical and physical data
FormulaC18H18F3N3O3
Molar mass381.355 g·mol−1
3D model (JSmol)
  • FC(F)(F)c1nc(no1)c3cc(c(OCCCc2onc(c2)C)c(c3)C)C
  • InChI=1S/C18H18F3N3O3/c1-10-7-13(16-22-17(27-24-16)18(19,20)21)8-11(2)15(10)25-6-4-5-14-9-12(3)23-26-14/h7-9H,4-6H2,1-3H3 Y
  • Key:KQOXLKOJHVFTRN-UHFFFAOYSA-N Y
 NY (what is this?)  (verify)

Pleconaril (Picovir) is an antiviral drug that was being developed by Schering-Plough for prevention of asthma exacerbations and common cold symptoms in patients exposed to picornavirus respiratory infections. Pleconaril, administered either orally or intranasally, is active against viruses in the Picornaviridae family, including Enterovirus and Rhinovirus. It has shown useful activity against the dangerous enterovirus D68.